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Abstract
Background: Studies on the effects of (-)-hydroxycitric acid (HCA) in humans are controversial.
As differences in the HCA preparations may contribute to this apparent discrepancy, the aim of
the current study is to compare different HCA-containing preparations in adult Wistar rats.
Design: The effects of 3 different HCA-containing preparations (Regulator, Citrin K, Super
CitriMax HCA-600-SXS, all used at an effective HCA dose of 150 and 300 mg/kg, administered
intragastrically) on food intake and body weight were studied in adult male Wistar rats. The efficacy
was tested under 2 different experimental conditions: 1) after a single dose administration and 2)
during repeated administration for 4 subsequent days.
Results: Regulator and Citrin K significantly reduced food intake in both experimental setups,
while Super CitriMax HCA-600-SXS was less effective. When administered for 4 subsequent days
Regulator and Citrin K diminished body weight gain.
Conclusion: Regulator and Citrin K were shown to be potent inhibitors of food intake in rats,
whereas Super CitriMax HCA-600-SXS showed only small and more inconsistent effects. The
striking differences in efficacy between these 3 preparations indicate that low doses of a relatively
low-effective HCA preparation may have contributed to the lack of efficacy as found in several
human studies.
Background
(-)-Hydroxycitric acid (HCA) is widely used as an ingredi-
ent for nutritional supplements aimed at reduction of
food intake, appetite and body weight. However, studies
on the effects of HCA in humans are controversial. Four
placebo-controlled studies support the efficacy of HCA in
man. In these studies, HCA administration led to
increased loss of body weight and appetite reduction
[1,2], decreased energy intake [3] and increased fat oxida-
tion [4]. In addition, one placebo-controlled study
reported increased loss of body weight after combined
treatment of HCA and chromium [5]. In contrast, several
other studies have not confirmed these proposed effects of
HCA on gain of body weight [6-10], energy intake [8-10]
or substrate utilization [11,12] in man.
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results of the human studies on the efficacy of HCA. First,
the doses used in the human studies are highly variable,
typically ranging from 5 – 40 mg/kg HCA per day whereas
in one trial a dose as high as 250 mg/kg was used [12].
Second, differences in HCA preparations or production
processes may also contribute to above-mentioned incon-
sistency in the results. For instance, HCA may occur either
in open chain or in a lactone form. Since the lactone form
has shown to be a very less effective inhibitor of the citrate
cleavage enzyme [13], different preparations attempt to
prevent cyclization of HCA into its (ineffective) lactone by
using different counter-ions (such as sodium, calcium or
potassium).
To obtain some insight into the difference in efficacy of
commercially available HCA preparations, we studied the
effects of three different HCA preparations on voluntary
food intake and body weight in conscious rats. The prod-
uct names of these preparations were: Regulator, Citrin K




All experimental protocols were approved by the Animal
Experiments Ethical Committee DEC-Consult, Bilthoven,
the Netherlands. Male Wistar rats (HsdCpb:WU, Harlan,
the Netherlands) aged 3 months and weighing 290–320
gram at arrival were used. The rats were kept at 20 ± 1°C,
with lights on from 23.00 h (ZT 0.00) until 11.00 h (ZT
12.00), and with water and RMH-B standard lab chow,
containing (w/w) 24% protein, 52% carbohydrates and
6% fat (Hope Farms, Woerden, the Netherlands) ad libi-
tum unless mentioned otherwise.
The rats received a permanent silicone cannula (I.D. 0.6
mm, O.D. 1.2 mm) in the stomach under Isoflurane/oxy-
gen/nitrogen oxide anesthesia according to the method
described by Strubbe et al. [14]. This was done to allow
stress-free intragastric (ig) administration of components
to freely moving rats. The animals were allowed to recover
for at least one week after surgery.
(-)Hydroxycitric acid preparations
The following preparations were used: (1) Regulator, a
synthetic produced product, which contains 97% of a tri-
Cumulative food intake in rats up to 46 hrs after a single intragastric administration of vehicle or 310 mg/kg Regulator (n = 6)Figure 1
Cumulative food intake in rats up to 46 hrs after a single intragastric administration of vehicle or 310 mg/kg Regulator (n = 6). 
* p < 0.05, **p < 0.01Page 2 of 9
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land), (2) Citrin K, an extract of Garcinia cambogia, which
contains 50% HCA (Sabinsa Corporation, New Jersey,
USA), with potassium as its primary mineral (28 g/100 g)
and (3) Super CitriMax HCA-600-SXS (abbreviated as Cit-
riMax), an extract of Garcinia cambogia, which contains
60% HCA (Interhealth Nutraceuticals Incorporated, Con-
cord, California), containing K+ (15 g/100 g) and Ca2+ (11
g/100 g). To test whether the effects are specific to HCA,
its structural analogue (4) tri-potassium citrate (Merck
Eurolab B.V., Darmstadt, Germany) was used for
comparison.
At a concentration of 75 mg HCA/ml demineralized
water, the osmotic values of all preparations were 0.545
mOsm/l for Regulator, 0.507 mOsm/l for Citrin K, 0.265
mOsm/l for CitriMax and 0.490 mOsm/l for an equimo-
lar solution of tri-potassium citrate in demineralized
water.
Experimental design
Two types of experiments were performed to study the
potential differences in efficacy between the different
HCA preparations. The first series of experiments focused
on the effect of one single administration of each prepara-
tion on food and water intake for the following 46 hrs in
a 4 days placebo-controlled crossover experiment. In the
second series of experiments, HCA was given twice a day
for 4 days to study effects of repeated doses of the compo-
nent on food and water intake. In both studies, rats were
housed individually in cages in which food and water
intake was monitored online (UgoBasile, Comerio, Italy).
Single administration
4 groups of 6 animals were used; within each group 2 sin-
gle experiments were done. Each single experiment lasted
for 4 days (96 hours). On day 1, food was removed 2
hours before dark onset (ZT 10.00). At ZT 11.30 randomly
assigned rats received either a single bolus of the test com-
ponent (dissolved in a total volume of 1 ml water) or a
single bolus of isovolumic amount of water alone through
the gastric cannula. At ZT 12.00 food was returned, and
food and drink intake were monitored at 1, 2, 3, 4, 5, 6,
12, 24 and 46 hrs after administration. This period of 46
hrs was a washout period at the same time. On day 3 the
protocol of day 1 was repeated. The rats that received the
Cumulative food intake in rats up to 46 hrs after a single intragastric administration of vehicle or 600 mg/kg Citrin K (n = 6)Figure 2
Cumulative food intake in rats up to 46 hrs after a single intragastric administration of vehicle or 600 mg/kg Citrin K (n = 6). * 
p < 0.05, **p < 0.01Page 3 of 9
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Body weight was registered daily. In this way each dose of
each HCA preparation was tested with regard to it's own
vehicle treatment in a crossover experiment.
Each HCA preparation was tested, in a group of 6 animals,
at two doses corresponding to 150 and 300 mg HCA/kg
body weight. Thus, three groups of 6 animals were used to
test Regulator at doses of 155 and 310 mg/kg, Citrin K at
300 and 600 mg/kg and CitriMax at 250 and 500 mg/kg,
respectively. In the fourth group of 6 animals tri-potas-
sium citrate, first, was tested at a dose of 475 mg per kg
body weight (corresponding to the molarity of 300 mg/kg
HCA) in comparison with vehicle treatment. Second, tri-
potassium citrate (475 mg/kg) was tested in comparison
with Regulator (310 mg/kg).
Repeated administration
To study the effects of long-term administration of the dif-
ferent HCA preparations, HCA or vehicle was adminis-
tered intragastric twice daily for 4 subsequent days (at ZT
11.30 and ZT 17.00). Body weight and food intake were
monitored during the 4 days of ig HCA-administration
and the 3 days thereafter at ZT 10.00.
For logistic reasons, the long term studies were performed
in two subsequent series of experiments. In the first set of
experiments (n = 15, for each treatment n = 5) vehicle,
Regulator and CitriMax and in the second set (n = 27, for
each treatment n = 9) vehicle, Regulator and Citrin K were
tested. All tested doses corresponded to the dose of 300
mg HCA/kg body weight.
Data analysis
In the single administration experiments, food intake
were analyzed for the crossover experiments by a four-way
ANOVA test with the factors, group of treatment order,
animals within group, period and type of vehicle treat-
ment, all per HCA preparation. First, the difference
between time period and beginning was analyzed to test
the possibility of a carryover effect. Because of the absence
of a carryover effect, the type of vehicle treatment effects
can be tested in the crossover experiment.
To compare the food intake results of the different HCA
preparations in the single administration experiments, the
delta (= difference) between treatment and vehicle on t =
24 hrs was calculated. To make comparisons between the
Cumulative food intake in rats up to 46 hrs after a single intragastric administration of vehicle or 500 mg/kg Super CitriMax HCA-600-SXS (n = 6)Figure 3
Cumulative food intake in rats up to 46 hrs after a single intragastric administration of vehicle or 500 mg/kg Super CitriMax 
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independent sample t-test with equal variances.
In the single administration experiments, bodyweight and
water intake were also analyzed for the crossover experi-
ments by a four-way ANOVA test, per HCA preparation.
In the repeated-administration experiments, the effects of
HCA treatment on food intake, water intake and body
weight were analyzed by a one-way ANOVA test. P values
less than 0.05 were regarded significant. Data are pre-
sented as mean ± SEM.
Results
Single administration
Cumulative food intake was significantly reduced after
intragastric administration of 310 mg/kg Regulator (figure
1) and 600 mg/kg Citrin K (figure 2). CitriMax (500 mg/
kg) tended to decrease food intake (figure 3), reaching sig-
nificance at t = 2 h. The low doses of Citrin K (300 mg/kg)
and Regulator (155 mg/kg) showed no effect on food
intake, CitriMax (250 mg/kg) reduced food intake only at
t = 2 h (table 1).
To enable comparison between the effects of the different
HCA treatments, the difference between 24 hrs cumula-
tive food intake after component treatment and after vehi-
cle treatment was calculated for each HCA source (defined
as delta, data shown in table 2). The negative delta's for
Regulator (310 mg/kg) and Citrin K (600 mg/kg), imply-
ing a decreased food intake after HCA administration
when compared to vehicle, were significantly different
from the positive delta for CitriMax (500 mg/kg).
Figure 4a shows that 475 mg/kg tri-potassium citrate had
no effect on cumulative food intake compared to vehicle
treatment. Regulator (310 mg/kg) decreased cumulative
food intake compared to tri-potassium citrate (figure 4b).
No effect on body weight and water intake was observed
in any of the experiments (data not shown).
Repeated administration
The effects of repeated administration of the high doses of
the three preparations on food intake were comparable to
the data of the single bolus experiments. Both Regulator
and Citrin K significantly reduced cumulative food intake
at days 1–4, whereas CitriMax did not reduce food intake
(figure 5 and 6). Three days after the last administration,
food intake was still significantly lower after Regulator
and Citrin K treatment (figure 5 and 6). Figure 5 also
shows that the cumulative food intake during and after
Regulator treatment was significantly lower than during
and after CitriMax treatment.
Regulator resulted in a significantly lower gain of body
weight compared to vehicle at day 2 and 4. Citrin K signif-
icantly reduced gain of body weight compared to vehicle
at day 1, 2 and 4 (data not shown).
Discussion
This study shows that three commercially available HCA
preparations exert striking differences in efficacy in inhib-
iting voluntary food intake in rats. Regulator and Citrin K
were potent suppressants of food intake, both after a sin-
gle bolus and after repeated administration, whereas Cit-
riMax exerted much smaller effects on food intake.
Table 1: Cumulative food intake in rats after a single intragastric administration of vehicle or different HCA preparations
Regulator (155 mg/kg) Citrin K (300 mg/kg) Super CitriMax HCA-600-SXS (250 mg/kg)
Vehicle Regulator Vehicle Citrin K Vehicle CitriMax
A t = 1 h 2.9 ± 0.6 2.9 ± 0.4 2.9 ± 0.7 2.5 ± 0.6 2.9 ± 0.6 2.7 ± 0.4
t = 2 h 5.7 ± 0.4 4.6 ± 0.5 4.2 ± 0.6 3.5 ± 0.6 4.3 ± 0.6 3.6 ± 0.7*
t = 3 h 6.9 ± 0.6 6.0 ± 0.2 6.0 ± 0.9 5.0 ± 0.8 6.2 ± 0.5 5.2 ± 0.6
t = 6 h 10.4 ± 0.8 10.4 ± 0.5 9.7 ± 0.9 9.3 ± 0.4 9.3 ± 0.7 9.2 ± 0.6
t = 24 h 22.6 ± 0.8 23.6 ± 0.7 23.8 ± 0.7 23.0 ± 1.1 21.1 ± 1.2 21.5 ± 0.7
Regulator (310 mg/kg) Citrin K (600 mg/kg) Super CitriMax HCA-600-SXS (500 mg/kg)
Vehicle Regulator Vehicle Citrin K Vehicle CitriMax
B t = 1 h 3.3 ± 0.5 2.5 ± 0.1 2.8 ± 0.5 2.8 ± 0.4 2.5 ± 0.7 1.9 ± 0.4
t = 2 h 6.4 ± 0.7 3.6 ± 0.3** 4.9 ± 0.8 3.6 ± 0.6 4.1 ± 0.2 2.7 ± 0.7**
t = 3 h 7.8 ± 0.8 4.9 ± 0.3** 6.8 ± 0.8 3.6 ± 0.6** 5.6 ± 0.5 5.0 ± 0.9
t = 6 h 12.1 ± 1.0 8.7 ± 0.9* 11.2 ± 0.6 7.4 ± 0.5** 9.2 ± 0.8 7.9 ± 0.8
t = 24 h 24.8 ± 1.2 20.9 ± 1.1** 25.6 ± 1.0 23.0 ± 0.8* 19.6 ± 1.2 20.0 ± 0.6
For each HCA preparation n = 6, * p < 0.05, ** p < 0.01Page 5 of 9
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Citrin K, but not CitriMax, reduced gain of body weight.
Many of the peer-reviewed human studies on HCA, which
report a lack of efficacy, used a CitriMax preparation as
their source [9,10,12] at doses that were considerably
lower than used in the present animal study, even when
corrected for differences in metabolic rate. High doses of
(CitriMax) HCA, however, have been shown to be effec-
Cumulative food intake in rats up to 46 hrs after a single intragastric administration of A. vehicle or 475 mg/kg tri-potassium citrate (n = 6)Figure 4
Cumulative food intake in rats up to 46 hrs after a single intragastric administration of A. vehicle or 475 mg/kg tri-potassium 
citrate (n = 6). B. 475 mg/kg tri-potassium citrate or 310 mg/kg Regulator (n = 6). * p < 0.05, **p < 0.01Page 6 of 9
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that low doses of a relatively low-effective HCA prepara-
tion may have contributed to the lack of efficacy in several
human studies.
The results of the current study are in line with earlier
observations that HCA reduces food intake in rats [15-22].
Most of the early rat studies had not been carried out with
the above-mentioned preparations; instead, a tri-sodium
salt of HCA was used [15-18]. To our knowledge, no pub-
lished rat studies used Regulator or Citrin K, while only
the recent studies of Leonhardt et al. have been carried out
with Super CitriMax HCA-600-SXG [19,20,22]. In these
studies, Super CitriMax-600-SXG significantly inhibited
food intake in rats, in contrast to the results obtained in
our present studies. Differences in the experimental setup
may underlie this apparent discrepancy. In their studies a
different rat strain and a different experimental setup (10
days supplementation after substantial, fasting-induced
body weight loss) were used. Also, a different CitriMax
preparation (SXG instead of SXS) was used at a dose that
was considerably higher than the maximal dose used in
our single-dose administration studies (around 1000 mg/
kg versus 500 mg/kg).
The cause of the differences in efficacy between the vari-
ous HCA preparations remains speculative. In this study,
it cannot simply be explained by differences in the relative
HCA content of the used preparations. Regulator (97%
pure for HCA) was equally effective as Citrin K (50% pure
for HCA). Citrin K was more effective than CitriMax (60%
pure for HCA). It cannot be excluded that the 40% non-
HCA content of CitriMax contains component(s) that
interfered with the suppressive effect of HCA on food
intake. Alternatively, the extraction method may have
resulted in an increased formation of (-)-HCA lactones,
which are less potent inhibitors of the citrate cleavage
enzyme [13].
It has been suggested that minerals play an important role
in regulating the stability, bio-availability or solubility of
HCA. In contrast to the two other more effective HCA
sources, CitriMax has relatively a high calcium and rela-
tively a low potassium content. Regulator and Citrin K
Cumulative food intake in rats during intragastric treatment twice daily for 4 subsequent days (day 1–4) and day 3 thereafter (day 7) with vehicle, 310 mg/kg Regulato  or 500 mg/kg Super CitriMax HCA-600-SXS (for each treatment n = 5)Figure 5
Cumulative food intake in rats during intragastric treatment twice daily for 4 subsequent days (day 1–4) and day 3 thereafter 
(day 7) with vehicle, 310 mg/kg Regulator or 500 mg/kg Super CitriMax HCA-600-SXS (for each treatment n = 5). * p < 0.05, 
**p < 0.01Page 7 of 9
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high content of potassium. If, as has been suggested, cal-
cium reduces solubility and hinders bio-availability
[23,24], the high calcium content in CitriMax may have
negatively affected bio-availability or stability of the HCA
molecule, resulting in a lower efficacy. It is unlikely that
the high potassium content in the two other HCA sources
is directly responsible for the observed inhibition of food
intake, as tri-potassium citrate did not affect food intake.
The osmolarity of the CitriMax solution was considerably
lower than the osmolarity of the more effective Regulator
and Citrin K solutions. It has been suggested that osmolar-
ity plays an important role in the regulation of satiety.
Ingestion of hypertonic solutions decreased subsequent
food intake in pigs [25]. In humans, the non-absorbable
fructose stereoisomer D-tagatose inhibited food intake
which may have been caused by the osmotic effects of the
unabsorbed D-tagatose [26]. However, as the osmolarity
of the ineffective tri-potassium citrate was as high as the
osmolarity of Regulator and Citrin K, differences in osmo-
larity cannot solely account for the differences in efficacy
of the various preparations used in this study.
It should be noted, however, that a decrease in food intake
as a result of induction of malaise or discomfort by any of
the used HCA sources cannot be excluded. Still, previous
studies on the occurrence of conditioned taste aversion
after HCA administration concluded that the food intake
reducing effects of HCA cannot be solely explained by the
induction of discomfort [27]. Accordingly, no behavioral
signs indicating lack of well-being were recognized during
these experiments.
In summary, this study shows that different commercially
available HCA preparations show differences in their
potency: Regulator and Citrin K are potent inhibitors of
food intake in rats, whereas similar doses of CitriMax
hardly showed any effect on food intake. As most of the
(ineffective) human studies used low dose CitriMax prep-
arations, the present study may indicate that low doses of
a relatively low-effective HCA preparation may have con-
tributed to the lack of efficacy in several human studies.
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